Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

24.40 -0.56 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,073,154
Open 24.83
Bid (Size) 24.40 (64)
Ask (Size) 24.41 (1)
Prev. Close 24.96
Today's Range 24.32 - 25.06
52wk Range 21.62 - 44.32
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024
BBIO stock results show that BridgeBio Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-39.68%
-39.68%
1 Month
-5.90%
-5.90%
3 Month
-17.34%
-17.34%
6 Month
-32.13%
-32.13%
1 Year
-15.04%
-15.04%

More News

Read More
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Why BridgeBio Pharma Stock Is Trading Lower Tuesday
Via Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Via Benzinga
Masters In Trading - Saturday, June 22
Via Talk Markets
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The 3 Best Biotech Stocks to Buy in June 2024
Via InvestorPlace
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
Via Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
Via Investor's Business Daily
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.